Karyopharm Therapeutics Valuation
| KPTI Stock | USD 0.83 0.02 2.35% |
Today, the firm appears to be overvalued. Karyopharm Therapeutics secures a last-minute Real Value of $0.7 per share. The latest price of the firm is $0.83. Our model forecasts the value of Karyopharm Therapeutics from analyzing the firm fundamentals such as Return On Equity of -8.91, current valuation of 166.64 M, and Profit Margin of (0.59) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Karyopharm Therapeutics' valuation include:
Price Book 12.0484 | Enterprise Value 166.6 M | Enterprise Value Ebitda (1.85) | Price Sales 0.7032 | Enterprise Value Revenue 1.1226 |
Overvalued
Today
Please note that Karyopharm Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Karyopharm Therapeutics is based on 3 months time horizon. Increasing Karyopharm Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Karyopharm Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Karyopharm Stock. However, Karyopharm Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.83 | Real 0.7 | Target 6.67 | Hype 0.83 | Naive 0.85 |
The intrinsic value of Karyopharm Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Karyopharm Therapeutics' stock price.
Estimating the potential upside or downside of Karyopharm Therapeutics helps investors to forecast how Karyopharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Karyopharm Therapeutics more accurately as focusing exclusively on Karyopharm Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Karyopharm Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Karyopharm Therapeutics Cash |
|
Karyopharm Valuation Trend
Karyopharm Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Karyopharm Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Karyopharm Therapeutics Total Value Analysis
Karyopharm Therapeutics is now anticipated to have valuation of 166.64 M with market capitalization of 104.39 M, debt of 177.02 M, and cash on hands of 170.85 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Karyopharm Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
166.64 M | 104.39 M | 177.02 M | 170.85 M |
Karyopharm Therapeutics Investor Information
About 50.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.05. Karyopharm Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Karyopharm Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Karyopharm Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Karyopharm Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Karyopharm Therapeutics has an asset utilization ratio of 60.74 percent. This signifies that the Company is making $0.61 for each dollar of assets. An increasing asset utilization means that Karyopharm Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Karyopharm Therapeutics Ownership Allocation
Karyopharm Therapeutics maintains a total of 125.31 Million outstanding shares. 30% of Karyopharm Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Karyopharm Therapeutics Profitability Analysis
The company reported the previous year's revenue of 146.03 M. Net Loss for the year was (143.1 M) with profit before overhead, payroll, taxes, and interest of 151.86 M.About Karyopharm Therapeutics Valuation
An absolute valuation paradigm, as applied to Karyopharm Stock, attempts to find the value of Karyopharm Therapeutics based on its fundamental and basic technical indicators. By analyzing Karyopharm Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Karyopharm Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Karyopharm Therapeutics. We calculate exposure to Karyopharm Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Karyopharm Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 141.1 M | 148.1 M | |
| Pretax Profit Margin | (0.98) | (1.03) | |
| Operating Profit Margin | (0.89) | (0.93) | |
| Net Loss | (0.98) | (1.03) | |
| Gross Profit Margin | 0.97 | 1.01 |
Karyopharm Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 114.2 M |
Karyopharm Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Karyopharm Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Karyopharm we look at many different elements of the entity such as Karyopharm's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Karyopharm Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Karyopharm Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Karyopharm Therapeutics' worth.Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |